Psoriasis Knowledge Centre relaunches on Medthority.com
The Psoriasis Knowledge Centre provides a comprehensive guide to the condition, delving into established topical, systemic and biologic treatments available for psoriasis as well as novel treatments, such as TNFα and interleukin antagonists.
You can delve into topics which uncover Disease Awareness, enabling you to learn about the trigger factors, comorbidities, the burden of psoriasis and the role of cytokines.
Read more about guidelines and management information on how to measure the response to treatment.
Discover how recent advances mean there are a number of new treatments available which target different signalling pathways including both TNFα inhibitors and interleukin-based therapies.
When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.
Related news and insights
Protagonist Therapeutics, Inc. announced two additional Phase III studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluating JNJ 2113 (formerly PN 235) in head-to-head comparisons against deucravacitinib, an oral TYK2 inhibitor, in patients with moderate-to-severe psoriasis
Protagonist Therapeutics, Inc. announced the achievement of a $50 million milestone event under its license and collaboration agreement with Janssen Biotech, Inc., a Johnson & Johnson company
UCB, a global biopharmaceutical company, announced that the FDA has approved Bimzelx (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.